Himani Tandon

About

Himani is a Senior Scientist with over a decade of experience in life sciences, specializing in computational biology and biophysics. She holds a Ph.D. from the Indian Institute of Science, Bangalore, and completed a postdoctoral fellowship at the MRC Laboratory of Molecular Biology, Cambridge, UK. Her research expertise spans protein structure-function analysis, cell reprogramming, and transcriptomics.
Currently, Himani is focused on computational drug discovery, utilizing AI/ML techniques to model the properties of drug candidates, including small molecules and peptides. She is also deeply involved in 3D ligand-based and structure-based drug design. With a strong foundation in statistical and analytical approaches, she systematically analyzes complex biological data to drive innovation in these fields.
Himani's research has been published in several peer-reviewed journals, and she is dedicated to making impactful contributions to drug discovery and computational biology.

Employment

• Optibrium (United Kingdom) Senior Scientist
  2023 - Present
• MRC Laboratory of Molecular Biology Post doctoral scientist
  2020 - 2023
• Institute of Microbial Technology CSIR-JRF
  2013 - 2014
• Persistent Systems Ltd Bioinformatics Domain Analyst
  2012 - 2013

Education

• Indian Institute of Science PhD
  2014 - 2019
• Pondicherry University M.Sc Bioinformatics
  2010 - 2012

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• Structure-based pose prediction: Non-cognate docking extended to macrocyclic ligands
  Journal of Computer-Aided Molecular Design 2024 DOI: 10.1007/s10822-024-00574-0
  +Save
• Single-Site Phosphorylation Elicits Structural, Dynamic, and Accessibility Changes in Proteins at both Proximal and Distal Regions to the Phosphosite
  2023 DOI: 10.1101/2023.11.30.569386
  +Save
• SIRT6 transcriptionally regulates fatty acid transport by suppressing PPARγ
  Cell Reports 2021 DOI: 10.1016/j.celrep.2021.109190
  +Save
• Transient association between proteins elicits alteration of dynamics at sites far away from interfaces
  Structure 2021 DOI: 10.1016/j.str.2020.11.015
  +Save
• Molecular and Structural Basis of Cross-Reactivity in M. tuberculosis Toxin–Antitoxin Systems
  Toxins 2020 DOI: 10.3390/toxins12080481
  +Save
• Bioinformatic and mutational studies of related toxin–antitoxin pairs in Mycobacterium tuberculosis predict and identify key functional residues
  Journal of Biological Chemistry 2019 DOI: 10.1074/jbc.RA118.006814
  +Save
• Mycobacterium tuberculosis Rv0366c-Rv0367c encodes a non-canonical PezAT-like toxin-antitoxin pair
  Scientific Reports 2019 DOI: 10.1038/s41598-018-37473-y
  +Save
• A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage.
  Antiviral research 2018 DOI: 10.1016/j.antiviral.2017.12.004
  +Save
• Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
  The Journal of general virology 2017 DOI: 10.1099/jgv.0.000735
  +Save
• AVP-IC50 Pred: Multiple machine learning techniques-based prediction of peptide antiviral activity in terms of half maximal inhibitory concentration (IC50).
  Biopolymers 2015 DOI: 10.1002/bip.22703
  +Save